Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Net Cash Flow (2019 - 2025)

Cyclerion Therapeutics has reported Net Cash Flow over the past 7 years, most recently at $1.6 million for Q3 2025.

  • Quarterly results put Net Cash Flow at $1.6 million for Q3 2025, up 191.03% from a year ago — trailing twelve months through Sep 2025 was $1.7 million (up 127.21% YoY), and the annual figure for FY2024 was -$4.3 million, up 25.54%.
  • Net Cash Flow for Q3 2025 was $1.6 million at Cyclerion Therapeutics, up from -$633000.0 in the prior quarter.
  • Over the last five years, Net Cash Flow for CYCN hit a ceiling of $25.1 million in Q2 2021 and a floor of -$13.0 million in Q1 2021.
  • Median Net Cash Flow over the past 5 years was -$1.9 million (2024), compared with a mean of -$3.1 million.
  • Peak annual rise in Net Cash Flow hit 336.5% in 2021, while the deepest fall reached 185.52% in 2021.
  • Cyclerion Therapeutics' Net Cash Flow stood at -$8.5 million in 2021, then increased by 17.72% to -$7.0 million in 2022, then surged by 78.08% to -$1.5 million in 2023, then skyrocketed by 123.36% to $360000.0 in 2024, then soared by 333.89% to $1.6 million in 2025.
  • The last three reported values for Net Cash Flow were $1.6 million (Q3 2025), -$633000.0 (Q2 2025), and $407000.0 (Q1 2025) per Business Quant data.